Antiproliferative role of vitamin D and its analogs - A brief overview

Molecular and Cellular Biochemistry

Volumn 253, Issue 1-2, 2003, Pages 247-254

  Banerjee, Pratik ^a   Chatterjee, Malay ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Apoptosis; Cancer; Cell cycle; Cellular proliferation; Vitamin D

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCIPOTRIOL; CALCITRIOL; CALCIUM; CB 966; RO 22 3790; RO 24 2637; RO 24 5531; RO 25 4020; RO 25 5317; RO 25 6760; RO 25 9022; SECOSTEROID; SEOCALCITOL; STEROID HORMONE; TX 522; TX 527; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

APOPTOSIS; BIOCHEMISTRY; BONE MINERALIZATION; BREAST CANCER; CALCIUM HOMEOSTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER RISK; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EXPERIMENTAL MODEL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPERCALCEMIA; INHIBITION KINETICS; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; PATIENT MONITORING; PROSTATE CANCER; REVIEW; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CELL DIVISION; HUMANS; HYPERCALCEMIA; NEOPLASMS; RECEPTORS, CALCITRIOL; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0142181197     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026072118217     Document Type: Review

References (91)

1. Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989
2. Bouillon R, Okamura WH, Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995
3. 3. Biochem J 316: 361-371, 1996
4. 3 in T lymphocytes. J Immunol 168: 1154-1166, 2002
5. 3. J Steroid Biochem Mol Biol 53: 599-602, 1995
6. Rigby WF: The immunobiology of vitamin D. Immunol Today 9: 54-58, 1988
7. 3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164: 4443-4451, 2000
8. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405-2411, 2000
9. 3 receptors in human leukocytes. Science 221: 1181-1183, 1983
10. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells. J Cell Biol 76: 1-6, 1985
11. 3 receptors: Gene regulation and genetic circuitry. FASEB J 2: 3043-3053, 1988
12. Niles RM: Use of vitamins A and D in chemoprevention and therapy of cancer: Control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol 375: 1-15, 1995
13. Norman AW: Vitamin D. In: R. Dulbecco (ed). Encyclopedia of Human Biology. Academic Press, Orlando, FL, 1997, pp 749-762
14. DeLuca HF, Zierold C: Mechanisms and functions of vitamin D. Nutr Rev 56: S4-S10, 1998
15. 3 response elements. In: A.W. Norman, R. Bouillon, M. Thomasset (eds). Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone. University of California, Riverside, 1997, pp 268-275
16. Weitberg AB, Weizman SA, Clark FP, Stossel TP: Effects of anti-oxidants on oxidant-induced sister chromatid exchange. J Clin Invest 75: 1835-1841, 1985
17. Gerner JM, Domenech M: 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol. Clin Pathol 30: 144-150, 1977
18. Mawer EB, Hann JT, Beny JL, Davies M: Vitamin D metabolism in patients intoxicated with ergocalciferol. Clin Sci 68: 135-141, 1985
19. Rizzoli R, Storemann C, Ammann P, Banjour JP: Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronde therapy. Bone 15: 193-198, 1994
20. 3 for liver cancers. J Gastroenterol Hepatol 16: 333-337, 2001
21. Garland FC, Garland CF, Young JF: Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med 19: 614-622, 1990
22. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 2: 1176-1178, 1989
23. Schwartz GG, Hulka BS: Is Vitamin D deficiency a risk factor for possible for prostate cancer (hypothesis)? Anticancer Res. 0: 1307-1312, 1990
24. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA et al.: Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 11: 113-119, 2002
25. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S et al.: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in Japanese population. Cancer Res 60: 305-308, 2000
26. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN et al.: Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6: 498-504, 2000
27. Platz AE, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE et al.: Plasma 1,25-dihydroxy- and 5-hydroxyvitamin D and Adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 9: 1059-1065, 2000
28. 3 on the activity patterns of hepatic drug metabolizing enzymes in transplantable murine lymphoma. Cancer Invest 14: 328-334, 1996
29. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM et al.: Vitamin D receptor as an intestinal bile acid sensor. Science 296: 1313-1316, 2002
30. 3 a novel immunoregulatory hormone. Science 224: 1438-1448, 1984
31. 3. Cancer Res 54: 4057-4064, 1994
32. Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM: The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 7: 817-822, 1987
33. Thomas MG, Tebbutt S, Williamson RCN: Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33: 1660-1663, 1992
34. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 308: 697-711, 1995
35. WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406, 1994
36. 3 in HL60 cells. Cancer Res 56: 264-267, 1996
37. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W et al.: A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88: 2201-2209, 1996
38. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP: Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analog involves the induction of p21 waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19: 15-27, 1997
39. R : A new vitamin D resistant cell line. J Cell Biochem 82: 422-436, 2001
40. kip1 gene promoter that lacks vitamin D response elements. J Biol Chem 274: 32309-32317, 1999
41. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995
42. Liu W, Asa SL, Fantus IG, Walfish PG Ezzat S: Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 160: 511-519, 2002
43. 3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochim Biophys Res Commun 139: 1292-1298, 1986
44. Kohl NE, Conner MW, Gibbs JB, Graham SL: Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 22(suppl): 145-150, 1995
45. Clairmont A, Tessmann D, Stock A, Nicolai S, Stahl W, Sies H: Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear vitamin D receptor. Carcinogenesis 17: 1389-1391, 1996
46. Hotz-Wagenblatt A, Shalloway D: Gap junctional communication and neoplastic transformation. Crit Rev Oncog 4: 541-558, 1993
47. Yu W, Dahl G, Werner R: The connexin 43 gene is responsive to estrogen. Proc R Soc Land B Biol 255: 125-132, 1994
48. 3 reduces their tumorigenecity: A model for cancer chemoprevention. Proc Soc Exp Biol Med 215: 399-404, 1997
49. 3 precedes down regulation of the c-myc genes. J Cell Physiol 128: 171-179, 1986
50. Quack M, Clarin A, Binderup E, Bjorkling F, Hansen CM, Carlberg C: Structural variants of the vitamin D analog EB1089 reduce its ligand sensitivity and promoter selectivity. J Cell Biochem 71: 340-350, 1998
51. Mathiasen IS, Lademann U, Jäättelä M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59: 4848-4856, 1999
52. Elstner E, Israeli ML, Umiel T, Le J, Grillier I, Said J et al: Combination of potent 20-epi-vitamin D3 analog (KH 1060) with 9-cis-retinoic acid irreversibility inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56: 3570-3576, 1996
53. Shkenazi A, Dixit VM: Death receptor: Signalling and modulation. Science 281: 1305-1308, 1998
54. 3, retinoic acid and dexamethasone. Anti-Cancer Drugs 4: 201-208, 1993
55. 3, in human breast cancer cells. Cancer Res 48: 2734-2739, 1988
56. 3 derivatives and breast-tumor cell growth: Effect on intracellular calcium and apoptosis. Int J Cancer 61: 806-811, 1995
57. Wood AC, Waters CM, Garner A, Hickman JA: Changes in c-myc expression and the kinetics of dexamethane induced programmed cell death (apoptosis) in human lymphoid leukemia cells. Br J Cancer 69: 663-669, 1994
58. Brady M, Binderum J, Colston KW: EB 1089, a synthetic analog of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 125: 953-962, 1998
59. 3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371-3379, 2000
60. 1-S phase-controlling machinery. Mol Endocrinol 15: 1370-1380, 2001
61. 3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55: 1440-1446, 1995
62. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60: 2673-2679, 2000
63. 3 and EB 1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31-41, 1997
64. Rozen F, Pollak M: Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analog EB 1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15: 589-594, 1999
65. 5 in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer 36: 780-786, 2000
66. 3 stimulates activator protein-1-dependent caco-2 cell differentiation. J Biol Chem 274: 35505-35513, 1999
67. 3 are differentially modified by 9-cis retinoic acid. Cancer Res 56: 623-632, 1996
68. 3. Leuk Res 20: 161-167, 1996
69. 3 and its analogs inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1β production. J Clin Invest 100: 1716-1724, 1997
70. Kole KL, Gyetko MR, Simpson RU, Sitrin RG: Cacitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol 41: 585-591, 1991
71. Seol JG, Kim ES, Park WH, Jung CW, Kim BK, Lee YY. Telomerase activity in acute myelogenous leukaemia: Clinical and biological implications. Br J Haematol 100: 156-165, 1998
72. Song LN: Demonstration of vitamin D receptor expression in a human megakaryoblastic leukemia cell line: Regulation of vitamin D receptor mRNA expression and responsiveness by forskolin. J Steroid Biochem Mol Biol 57: 265-274, 1996
73. 3 suppresses the expression of the VCAM-1 receptor, VLA-4 in human leukemic HL-60 cells. Biochem Biophys Res Commun 255: 371-376, 1999
74. 3 analog, EB 1089 and TGF-β1 in NCI-H929 multiple myeloma cells. Int J Oncol 20: 533-542, 2002
75. KIP1. Blood 93: 2225-2233, 1999
76. 3 display increased CDK2 and CDK6 activity and shortened G1 phase. Oncogene 16: 2729-2737, 1999
77. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141: 2548-2556, 2000
78. 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20: 1860-1872, 2001
79. 3 and its analog EB1089. Int J Oncol 13: 137-143, 1998
80. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58: 277-288, 1996
81. 1 accumulation. Endocrinology 139: 1197-1207, 1998
82. 3 inhibits hepatic chromosomal aberrations, DNA strand breaks and specific DNA adducts during rat hepatocarcinogenesis. Cell Mol Life Sci 58: 1141-1149, 2001
83. 3 suppresses the effect of streptozotocin-induced diabetes during chemical rat liver carcinogenesis. Cell Biol Int 25: 227-237, 2001
84. 3 inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 81: 357-367, 2001
85. 3 inhibit placental glutathione S-transferase positive foci in rat liver carcinogenesis. Life Sci 68: 217-231, 2000
86. 3. Biochim Biophys Acta 1502: 273-282, 2000
87. 3 inhibit diethylnitrosamine-induced rat liver carcinogenesis. Chem Biol Interact 128: 1-18, 2000
88. 3 and its analogs on growth control and tumorigenesis. Front Biosci 6: D820-D848, 2001
89. Chatterjee M: Vitamin D and genomic stability. Mutat Res 475: 69-87, 2001
90. van den Bemd GJ, Chang GTG: Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3: 85-94, 2002
91. 3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 59: 4023-4029, 1999